Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously reported that among the 37 RING finger protein (RNF) family members,
RNF183
mRNA is specifically expressed in the kidney under normal conditions. However, the mechanism supporting its kidney-specific expression pattern remains unclear. In this study, we elucidated the mechanism of the transcriptional activation of murine
Rnf183
in inner-medullary collecting duct cells. Experiments with anti-
RNF183
antibody revealed that
RNF183
is predominantly expressed in the renal medulla. Among the 37 RNF family members,
Rnf183
mRNA expression was specifically increased in hypertonic conditions, a hallmark of the renal medulla.
RNF183
up-regulation was consistent with the activation of nuclear factor of activated T cells 5 (NFAT5), a transcription factor essential for adaptation to hypertonic conditions. Accordingly, siRNA-mediated knockdown of NFAT5 down-regulated
RNF183
expression. Furthermore, the -3,466 to -3,136-bp region upstream of the mouse
Rnf183
promoter containing the NFAT5-binding motif is conserved among mammals. A luciferase-based reporter vector containing the NFAT5-binding site was activated in response to hypertonic stress, but was inhibited by a mutation at the NFAT5-binding site. ChIP assays revealed that the binding of NFAT5 to this DNA site is enhanced by hypertonic stress. Of note, siRNA-mediated
RNF183
knockdown increased hypertonicity-induced
caspase-3
activation and decreased viability of mIMCD-3 cells. These results indicate that (i)
RNF183
is predominantly expressed in the normal renal medulla, (ii) NFAT5 stimulates transcriptional activation of
Rnf183
by binding to its cognate binding motif in the
Rnf183
promoter, and (iii)
RNF183
protects renal medullary cells from hypertonicity-induced apoptosis.
...
PMID:NFAT5 up-regulates expression of the kidney-specific ubiquitin ligase gene
Rnf183
under hypertonic conditions in inner-medullary collecting duct cells. 3041 37
RNF183
is a ubiquitin ligase containing RING-finger and transmembrane domains, and its expression levels are increased in patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice. Here, we further demonstrate that
RNF183
was induced to a greater degree in the dextran sulfate sodium (DSS)-treated IBD model at a very early stage than were inflammatory cytokines. In addition, fluorescence-activated cell sorting and polymerase chain reaction analysis revealed that
RNF183
was specifically expressed in epithelial cells of DSS-treated mice, which suggested that increased levels of
RNF183
do not result from the accumulation of immune cells. Furthermore, we identified death receptor 5 (DR5), a member of tumour necrosis factor (TNF)-receptor superfamily, as a substrate of
RNF183
.
RNF183
mediated K63-linked ubiquitination and lysosomal degradation of DR5. DR5 promotes TNF-related apoptosis inducing ligand (TRAIL)-induced apoptosis signal through interaction with caspase-8. Inhibition of
RNF183
expression was found to suppress TRAIL-induced activation of caspase-8 and
caspase-3
. Thus,
RNF183
promoted not only DR5 transport to lysosomes but also TRAIL-induced caspase activation and apoptosis. Together, our results provide new insights into potential roles of
RNF183
in DR5-mediated caspase activation in IBD pathogenesis.
...
PMID:Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation. 3188 78